menu
    • menu
    [{"orgOrder":0,"company":"Agilent Technologies","sponsor":"GI Innovation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"GI-101","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Agilent Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Agilent Technologies \/ Agilent Technologies","highestDevelopmentStatusID":"7","companyTruncated":"Agilent Technologies \/ Agilent Technologies"},{"orgOrder":0,"company":"Agilent Technologies","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Approved","graph3":"Agilent Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agilent Technologies \/ Agilent","highestDevelopmentStatusID":"12","companyTruncated":"Agilent Technologies \/ Agilent"},{"orgOrder":0,"company":"Agilent Technologies","sponsor":"Transcenta Holding","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Agilent Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Agilent Technologies \/ Agilent Technology Inc","highestDevelopmentStatusID":"10","companyTruncated":"Agilent Technologies \/ Agilent Technology Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by Agilent Technologies

    Menu

    Agilent Technologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Agilent Technologies

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Agilent Technologies

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Osemitamab,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Transcenta Holding

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Transcenta Collaborates with Agilent To Develop Companion Diagnostic for Osemitamab

                            Details : The collaboration aims to develop a CLDN18.2 companion diagnostic for phase III TST001 (osemitamab) with nivolumab and chemotherapy in patients with advanced gastroesophageal adenocarcinoma.

                            Brand Name : TST001

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 08, 2024

                            Lead Product(s) : Osemitamab,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Transcenta Holding

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Agilent Technologies

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Agilent Technologies

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abemaciclib,Tamoxifen Citrate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Eli Lilly

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2-...

                            Details : Based on results, Verzenio may require dose modification. Monitor patients for signs and symptoms of thrombosis and pulmonary embolism and treat as medically appropriate. Advise patients of potential risk to a fetus and to use effective contraception.

                            Brand Name : Verzenio

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 13, 2021

                            Lead Product(s) : Abemaciclib,Tamoxifen Citrate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Eli Lilly

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Agilent Technologies

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Agilent Technologies

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GI-101,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : GI Innovation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Agilent Announces MOU to Collaborate with GI Innovation for Biomarker Profiling in Phase 1/2 Study of Cancer I...

                            Details : The MOU establishes a framework in which the two companies will enter into a strategic partnership to explore potential genomic biomarkers of the tumor microenvironment in an early-phase trial of the investigational compound GI-101.

                            Brand Name : GI-101

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 02, 2020

                            Lead Product(s) : GI-101,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : GI Innovation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth